<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356160</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-256-0148</org_study_id>
    <nct_id>NCT01356160</nct_id>
  </id_info>
  <brief_title>GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy With GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response
      Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a
      and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus
      Infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the antiviral efficacy of response guided therapy.</measure>
    <time_frame>Through 24 weeks post-treatment</time_frame>
    <description>To evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as plasma HCV RNA &lt; Lower Limit of Quantification (LLoQ) at 24 weeks post-treatment) of response guided therapy (RGT) with GS-5885 + GS-9451 + PEG/RBV, or GS-5885 + PEG/RBV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of each regimen.</measure>
    <time_frame>Through 24 weeks post-treatment</time_frame>
    <description>The primary safety endpoint is any AE leading to permanent discontinuation of study drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize viral dynamics of GS-5885 and GS-9451 when administered with PEG and RBV.</measure>
    <time_frame>Through Day 10 on study</time_frame>
    <description>HCV RNA levels, pharmacokinetics and viral sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the viral resistance to GS-5885 and GS-9451 when administered in combination with PEG and RBV.</measure>
    <time_frame>12 or 24 weeks</time_frame>
    <description>Plasma samples will be collected and stored at each visit for possible resistance analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize steady state pharmacokinetics of GS-5885 and GS-9451 when administered with PEG and RBV.</measure>
    <time_frame>Through 48 weeks of treatment</time_frame>
    <description>Plasma concentrations of the study drug over time will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RGT with GS-5885 30 mg QD + GS-9451 200 mg QD + PEG/RBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RGT with GS-5885 30 mg QD + GS-9451 placebo QD + PEG/RBV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5885</intervention_name>
    <description>tablet, 30 mg QD</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9451</intervention_name>
    <description>tablet, 200 mg QD</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2a</intervention_name>
    <description>(solution for injection) 180 µg/week</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin tablet</intervention_name>
    <description>ribavirin tablet (weight based: 1000 mg/day &lt;75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9451 Placebo</intervention_name>
    <description>Placebo to match GS-9451 QD</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18-70 years of age

          -  Chronic HCV infection

          -  Subjects must have liver biopsy results (≤ 2 years prior to Screening) indicating the
             absence of cirrhosis.

          -  Monoinfection with HCV genotype 1

          -  HCV RNA &gt; 10^4 IU/mL at Screening

          -  HCV treatment naïve

          -  Candidate for PEG/RBV therapy

          -  Body mass index (BMI) 18-36 kg/m2, inclusive

          -  Agree to use two forms of highly effective contraception methods for the duration of
             the study and for 7 months after the last dose of study medication. Females of
             childbearing potential must have negative pregnancy test at Screening and Baseline.

        Exclusion Criteria:

          -  Pregnant female or male with pregnant female partner

          -  Exceed defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia,
             thyroid stimulating hormone (TSH)

          -  Diagnosis of autoimmune disease, decompensated liver disease, poorly controlled
             diabetes mellitus, significant psychiatric illness, severe chronic obstructive
             pulmonary disease (COPD), HIV, hepatitis B virus (HBV), hepatocellular carcinoma or
             other malignancy (with exception of certain resolved skin cancers), hemoglobinopathy,
             retinal disease, or are immunosuppressed.

          -  Subjects with current use of amphetamines, cocaine, opiates (e.g., morphine, heroin),
             or ongoing alcohol abuse are excluded. Patients on stable methadone or buprenorphine
             maintenance treatment for at least 6 months prior to Screening may be included into
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bittoo Kanwar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <disposition_first_submitted>November 26, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>November 26, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 20, 2013</disposition_first_posted>
  <last_update_submitted>January 2, 2014</last_update_submitted>
  <last_update_submitted_qc>January 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>Rapid Virologic Response</keyword>
  <keyword>Sustained Virologic Response</keyword>
  <keyword>Direct Acting Antiviral</keyword>
  <keyword>Combination Therapy HCV RNA</keyword>
  <keyword>Protease inhibitor</keyword>
  <keyword>Treatment naïve</keyword>
  <keyword>GS-5885</keyword>
  <keyword>GS-9451</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

